$ Value
$11K
Shares
6,000
Price
$2
Filed
Feb 19
Insider
Name
Bredt David
Title
Chief Scientific Officer
CIK
0002022087
Roles
Transaction Details
Transaction Date
2026-02-19
Code
M
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
393,075
Footnotes
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. | Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction. | 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Filing Info
Bredt David's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-19 | RAPP | M | $11K |
| 2026-02-19 | RAPP | M | $0 |
| 2026-02-17 | RAPP | ▼ | $25K |
| 2026-02-17 | RAPP | ▼ | $156K |
| 2026-02-17 | RAPP | ▼ | $65K |
| 2026-02-02 | RAPP | A | $0 |
| 2026-01-15 | RAPP | ▼ | $223K |
| 2026-01-15 | RAPP | ▼ | $5K |
| 2025-12-31 | RAPP | A | — |
| 2025-12-31 | RAPP | ▼ | $197K |
Other Insiders at RAPP (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Ignelzi Troy A.
Chief Financial Officer
|
— | — | 2026-02-02 |
|
Ceesay Abraham
Chief Executive Officer
|
— | $320K | 2026-02-18 |
| Third Rock Ventures V, L.P. | — | $17.2M | 2026-04-17 |
|
Sevigny Jeffrey
Chief Medical Officer
|
— | — | 2026-02-02 |
|
Gault Cheryl
Chief Operating Officer
|
— | $282K | 2026-03-30 |
|
Bredt David
Chief Scientific Officer
|
— | $247K | 2026-02-19 |
|
Yeleswaram Krishnaswamy
Chief Development Officer
|
— | $1.8M | 2026-04-17 |